Pipal

Pipal is a clinical-stage biotechnology company dedicated to developing advanced topical treatments for inflammatory skin conditions, with a primary focus on atopic dermatitis. The company's lead program, PTX-022, is a proprietary topical formulation of a phosphodiesterase 4 (PDE4) inhibitor designed to provide superior skin penetration and localized efficacy while minimizing systemic side effects. Founded by renowned scientists from MIT and Harvard, Pipal utilizes specialized drug delivery expertise to enhance the therapeutic profile of established pathways. The company is currently advancing its pipeline to provide patients with safer and more effective alternatives to traditional steroidal therapies. By focusing on optimized delivery, Pipal aims to redefine the standard of care for chronic dermatological diseases.